FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects

Main Inclusion Criteria: * Participant capable of giving signed informed consent * Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Participants are overtly healthy as determined by a medical evaluation including medical history without clinically relevant pathologies, physical examination, vital signs, ECG assessment, and clinical laboratory result * eGFR ≥ 90 mL/min and \< 160 mL/min for males or \< 150 mL/min for females * Body weight within 50.0 and 100.0 kg and BMI within 18.0 and 30.0 kg/m2 Main Exclusion Criteria: * History of any clinically-relevant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrine, haematologic, neuromuscular or allergic disease(s), metabolic disorder, cancer, cirrhosis, significant acute infection, local infection within 2 weeks of dose administration, * ECG: any history of clinically-significant ECG abnormalities, an uninterpretable ECG, or any of ECG abnormalities, unless considered not significant by the Investigator * Abnormalities in clinical chemical, haematological, or coagulation variables considered medically relevant by the Investigator, * Positive urine drug screen, positive breathalyzer for alcohol * Positive results in any of the following virology tests: HIV-1 and -2 antibodies, HBsAg, and anti-hepatitis C virus antibody * Positive SARS-CoV-2 antigen test * Women who are pregnant or nursing, * Donation or loss of over 500 mL of blood within sixty days prior to the first study drug administration, Part C with co-administration of meropenem: 1. History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders, 2. Known history of clinically-significant hypersensitivity or urticaria, or severe allergic reaction to β-lactam antibiotics, 3. History of Gilbert syndrome, 4. History of any severe antibiotic-associated superinfections,